In this study, 95 patients were randomized across five treatment arms with regimens of
MK-7009 300 mg or 600 mg twice daily,
MK-7009 600 mg or 800 mg once daily, or placebo, for 28 days. Patients in all treatment arms received standard doses of peg-IFN/RBV in combination with the MK-7009 or placebo regimens, and are continuing to receive peg-IFN/RBV for an additional 44 weeks. HCV RNA was measured by the HCV RNA PCR TaqMan 2.